Search company, investor...

Founded Year



Series B | Alive

Total Raised


Last Raised

$29.69M | 19 hrs ago

About Eligo Bioscience

Eligo Bioscience provides biotechnology services. It focuses on the development of biotherapeutics for microbiome precision editing. The company's service involves the use of in vivo gene editing technologies to target the microbiome and address diseases with high unmet needs. It was founded in 2014 and is based in Paris, France.

Headquarters Location

111 Avenue de

Paris, 75013,




Expert Collections containing Eligo Bioscience

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Eligo Bioscience is included in 2 Expert Collections, including Synthetic Biology.


Synthetic Biology

238 items

Companies involved in design and development of new biological parts, devices, and systems; as well as the re-design of existing biological systems.


Digital Health

10,585 items

The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.

Eligo Bioscience Patents

Eligo Bioscience has filed 44 patents.

The 3 most popular patent topics include:

  • molecular biology
  • genetics
  • biotechnology
patents chart

Application Date

Grant Date


Related Topics




Molecular biology, Genetics, Biotechnology, Molecular genetics, Genetic engineering


Application Date


Grant Date



Related Topics

Molecular biology, Genetics, Biotechnology, Molecular genetics, Genetic engineering



Latest Eligo Bioscience News

$30m for genetic medicine advancements

Dec 5, 2023

European Biotechnology Latest News © 18percentgrey - 05.12.2023 Eligo Bioscience secures $30m in series B funding, advancing its innovative gene-editing solutions targeting diseases linked to bacterial genes within the human microbiome. Eligo Bioscience SA has secured $30m in a series B funding round led by Sanofi Ventures. The funding includes support from new investor Bpifrance, a French public sector investment bank, and existing backers Khosla Ventures, American venture capital firm, and Seventure Partners, French venture capital firm, signifying the stride toward the company's evolution into a clinical-stage biotech entity. “This is a defining time for Eligo as this funding puts us in a strong position to make a significant leap in treating diseases by editing the genetic makeup of the human microbiome,” said Xavier Duportet, PhD, Chief Executive Officer of Eligo Bioscience. The funding will expedite the development of EB005, Eligo's program targeting moderate to severe acne vulgaris. It aims to generate early human data in a PhIb/IIa clinical trial and facilitate Eligo's expansion into various chronic diseases, including oncology. Eligo Bioscience's method of delivering genetic material to the microbiome in vivo goes beyond typical gene therapy, offering accurate modification of genetic elements within the human microbiome. This unique approach holds potential to alter the course of numerous chronic and life-threatening diseases associated with bacterial gene expression. Share

Eligo Bioscience Frequently Asked Questions (FAQ)

  • When was Eligo Bioscience founded?

    Eligo Bioscience was founded in 2014.

  • Where is Eligo Bioscience's headquarters?

    Eligo Bioscience's headquarters is located at 111 Avenue de, Paris.

  • What is Eligo Bioscience's latest funding round?

    Eligo Bioscience's latest funding round is Series B.

  • How much did Eligo Bioscience raise?

    Eligo Bioscience raised a total of $53.71M.

  • Who are the investors of Eligo Bioscience?

    Investors of Eligo Bioscience include Seventure Partners, Khosla Ventures, Bpifrance, Sanofi Ventures, CARB-X and 5 more.

  • Who are Eligo Bioscience's competitors?

    Competitors of Eligo Bioscience include Locus Biosciences and 1 more.


Compare Eligo Bioscience to Competitors

Synthego Logo

Synthego provides a genome engineering platform. The company provides platforms for science at scale, to access machine learning (ML), automation, and gene editing for creating medicines. Its primary customer base is in the healthcare and medical research industries. It was founded in 2012 and is based in Redwood City, California.

Adaptive Phage Therapeutics Logo
Adaptive Phage Therapeutics

Adaptive Phage Therapeutics runs a clinical-stage company focusing on the development of therapies to combat multi-drug-resistant bacterial infections. The company's main offering includes an ever-expanding collection of bacteriophages, which are viruses that infect bacteria, designed to adapt to and overcome emerging bacterial resistance. It was founded in 2016 and is based in Gaithersburg, Maryland.


Microbiotix is a company focused on the development of treatments for global intractable diseases such as multi-drug resistant bacterial infections, autoimmune diseases, and cancer, operating in the biotechnology and pharmaceutical industry. The company's main offerings include the development of bacteriophage-based super bacteria treatments and microbiome and phage-based treatments. They also provide a microbiota banking service. It was founded in 2016 and is based in Seoul, South Korea.

Locus Biosciences Logo
Locus Biosciences

Locus Biosciences operates as a precision medicine company. It develops bacteriophage-based products to precisely remove pathogenic bacteria from the human body and to leverage the microbiome to treat diseases across multiple therapeutic areas. It was founded in 2015 and is based in Morrisville, North Carolina.

Amyris Logo

Amyris (NASDAQ: AMRS) offers integrated renewable products by applying industrial synthetic biology to genetically modify microorganisms to serve as living factories. It designs microorganisms to produce defined molecules for use as renewable chemicals and transportation fuels. The company was founded in 2003 and is based in Emeryville, California. In August 2023, Amyris filed for bankruptcy.

Codon Devices

Codon Devices is engaged in the field of synthetic biology.


CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.